1. The plaintiff's appeal is dismissed.

2. The costs of appeal shall be borne by the Plaintiff.

The purport of the claim and appeal is the purport of the appeal.

1. The following facts may be found either in dispute between the parties or in full view of the purport of the entire pleadings in each entry in Gap evidence 1 to 3, Eul evidence 1 and 2:

1) The Plaintiff (hereinafter “Plaintiff”) was changed from C to October 31, 201, and was changed to the current trade name; and hereinafter “Plaintiff”) without distinguishing the previous and following changes.

A) The purpose of semiconductors and related products is to manufacture and sell semiconductors and related products. 2) Tae Young Pharmaceutical Co., Ltd. (hereinafter referred to as “Teo Young Pharmaceutical Co., Ltd.”) is a company established for the purpose of wholesale and retail of drugs, drug sales agency, etc.

B. On June 27, 2011, the Plaintiff entered into a joint project agreement with the Pacific Drugs (hereinafter “instant joint project agreement”) with the Plaintiff.

The main contents of the instant joint project agreement are as follows.

(1) At the request of the plaintiff for purchase for smooth entry into a new business of wholesale distribution of drugs, solar drugs shall be purchased and supplied to the plaintiff at a competitive price on the basis of the know-how with solar drugs, and the plaintiff shall sell the purchased drugs to medical institutions, distributors, etc.

(2) Article 3(a) of the Act provides that the Plaintiff shall immediately dispatch an order for the first-do volume to Tae Young medicine to ensure that normal business activities can be performed immediately after obtaining permission for the wholesale business of drugs, and such order items shall be secured prior to the acquisition of the Plaintiff’s order items so that Tae Young medicine can be supplied simultaneously with the Plaintiff’s permission.

In this regard, the plaintiff should pay the order price in advance to the Tae Young medicine.

(Article III(e)(c).

On July 15, 2011, the Plaintiff transferred KRW 2 billion to a bank account in the name of Tae Young medicine. D.

The commencement of the first-class medicine, such as the commencement of rehabilitation procedures for solar medicine, shall be September 201.